NCT05166109 - A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 7, 2022

Primary Completion Date

August 18, 2025

Study Completion Date

August 18, 2025

Conditions

Becker Muscular Dystrophy

Interventions

DRUG

Vamorolone

Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.

DRUG

Placebo

Placebo to Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.

Trial Locations (2)

University of Pittsburgh, Pittsburgh

Azienda Ospedale Universita Padova, Padua